apoptosis inducer

Apoptosisinducer 26 (compound [AgCl(dap2SH)(PPh3)2]) is a mononuclear Ag(I) ligand-based autophagy inducer that exhibits antibacterial and anticancer activities against various bacterial strains and cancer cell lines. This compound facilitates the accumulation of Ag(I) ions in the periphery of bacteria, effectively inhibiting the growth of both Gram-positive (+) and Gram-negative (-) bacteria. Additionally, Apoptosisinducer 26 can intercalate between the base pairs of CT DNA, inducing apoptosis in A549 cells. It also possesses radical scavenging properties, which helps prevent oxidative stress.

Apoptosisinducer 28 (Compound X1) is an apoptosis inducer with demonstrated in vitro anticancer activity. It arrests the cell cycle at the G1 phase, promoting cell death and inducing apoptosis by disrupting the mitochondrial membrane potential.

Apoptosis Inducer 29 (compound Y9) demonstrates anticancer efficacy in non-small cell lung cancer by inducing lysosomal dysfunction and apoptosis, and exhibits superior performance to Gboixn both in vitro and in vivo.

Apoptosisinducer 32 (Compound 7g) is an apoptosis inducer with a KD of 42 μM, demonstrating antitumor activity by causing significant morphological changes, such as membrane blebbing, nuclear fragmentation, and apoptotic body formation, in MDA-MB-231 cells. The IC50 values for Apoptosisinducer 32 are 4.77 μM in MCF-7 cells, 6.56 μM in MDA-MB-231 cells, and 337.8 μM in HEK cells.

Ferroptosis/apoptosis inducer-2 (compound D2) is an anticancer drug that has demonstrated anticancer activity both in vivo and in vitro.

Apoptosisinducer 19 (Compound 7g) is an apoptosis inducer. It enhances the expression of pro-apoptotic proteins (Bax and caspase-3) while downregulating anti-apoptotic protein (Bcl-2). Additionally, it increases cellular reactive oxygen species (ROS) levels and disrupts mitochondrial membrane potential (MMP). Apoptosisinducer 19 can be utilized in research on triple-negative breast cancer (TNBC).

Apoptosis inducer39 is an apoptosis inducer with IC50 values of 4.53 μM for MDA-MB-231 cells and 15.42 μM for A549 cells. It exhibits antitumor activity in vitro by reducing the expression of the anti-apoptotic protein Bcl-2 and increasing the expression of the pro-apoptotic protein Bax. Apoptosis inducer39 is applicable in breast cancer and non-small cell lung cancer research.

Apoptosis inducer42 is an apoptosis inducer that triggers late-stage apoptosis and inhibits the secretion of IL-6. It exhibits high cytotoxicity toward cancer cells and is applicable in cancer research, including studies on colon cancer.

Apoptosis inducer40 is an apoptosis (apoptosis) inducer that exhibits potent cytotoxic effects on Jurkat and NB4 cells, with IC50 values of 4.5 μM and 3.6 μM, respectively. It promotes apoptosis and arrests the cell cycle, making it applicable for cancer research, particularly in the study of acute myeloid leukemia (AML).

Apoptosis inducer 5D is a new type of inducer that induces cell death by activating the apoptosis of cancer cells.

Apoptosis inducer 10 is a potent compound with anti-proliferative activity that induces apoptosis in HeLa (cervical cancer) cells via a mitochondria-dependent endogenous pathway.

Apoptosis inducer 6 is an anticancer agent with broad-spectrum anticancer activity that induces apoptosis, which triggers cell death.

Apoptosis inducer 8 is a galectin-1 (gal-1)-mediated apoptosis inducer and a PET imaging agent that significantly reduces gal-1 protein levels and can be used in major lung cancer studies worldwide.

Apoptosis Inducer 5, a lignan enantiomer extracted from Crataegus pinnatifida, demonstrates cytotoxic properties through inducing apoptosis and autophagy in Hep3B cells.

Apoptosis Inducer 3 (Compound 3), a selective apoptosis triggering agent, induces both apoptosis and late-apoptosis phases, demonstrating cytotoxic effects against cancer cells [1].

Apoptosis Inducer 12 (Compound 3z) is a compound that promotes cell death via the mitochondrial pathway and is utilized in cancer research [1].

Apoptosis Inducer 11 (compound 3u) promotes apoptosis via the mitochondrial pathway and elicits a G2/M block alongside a marked reduction in the S phase within non-Hodgkin lymphoma cell lines [1].

Apoptosis Inducer 13 (Compound Ru4) promotes apoptosis in cancer cells while also suppressing their migration and invasion. Additionally, it facilitates the conversion of coenzyme NADH to NAD+, and elevates intracellular ROS levels [1].

Apoptosis Inducer 2 (Compound 2) primarily induces necrosis while exhibiting cytotoxic effects against cancer cells [1].

Apoptosisinducer 22 (QR-5) is a chemical compound that serves as an inducer of apoptosis, exhibiting IC50 values of 63.1 μM for SW480 colon cancer cells and 46.5 μM for HT29 colon cancer cells. It induces apoptosis by inhibiting the Wnt/β-catenin pathway in these cells. Apoptosisinducer 22 is utilized in research targeting colon cancer.

Apoptosisinducer 23 (compound 6e) is an apoptosis inducer with antitumor activity. This compound initiates cell apoptosis through mediated mitochondrial damage, playing a crucial role in lung cancer research.

Ferroptosis/apoptosis inducer-1 (compound 4d) acts as a dual inducer of both cell apoptosis (apoptosis) and iron-dependent cell death (ferroptosis). It promotes these processes by decreasing mitochondrial membrane potential and downregulating GPX4. Effective in vitro and in vivo, Ferroptosis/apoptosis inducer-1 significantly inhibits the proliferation and metastasis of triple-negative breast cancer (TNBC), playing a crucial role in cancer research.

Apoptosisinducer 24 (Compound 4) inhibits the proliferation of gastric cancer cells with an IC50 range of 1.2-4.8 μM. It arrests the cell cycle at the G2/M phase, induces apoptosis in BGC-823 cells, and causes mitochondrial dysfunction. In mice, Apoptosisinducer 24 exhibits antitumor activity without significant toxicity, having an LD50 of 91.2 mg/kg.

Apoptosisinducer 25 (Compound 4H) demonstrates potent anticancer capabilities by inhibiting the proliferation of BGC-823 cancer cells with an IC50 of 0.37 μM. It induces apoptosis in BGC-823 cells, causes mitochondrial dysfunction, and arrests the cell cycle at the G2/M phase. Additionally, Apoptosisinducer 25 exhibits favorable pharmacokinetic properties in rats.